David E. Griffith
David E. Griffith, MD, is a pulmonologist at National Jewish Health. Dr. Griffith is in the Division of Mycobacterial & Respiratory Infections.
Division of Mycobacterial & Respiratory Infections
Department of Medicine

Special Interests

My major areas of interest spanning more than 30 years are mycobacterial diseases, including both nontuberculous mycobacterial (NTM) disease and tuberculosis, and bronchiectasis. I started my career in NTM lung disease with the invaluable encouragement of Dr. Richard Wallace more than 30 years ago. In the mid 1980’s there were very few centers interested in NTM lung disease in the United States or anywhere else in the world. Over the last 3 decades I have participated in multiple clinical trials and research projects that have resulted in the establishment of standards for treatment of patients with NTM diseases. I have been fortunate to work in the top two-referral centers for NTM disease in the United States where consultations are provided regionally and nationally to clinicians and patients. I have participated in the development of 3 iterations of nontuberculous mycobacterial disease diagnosis and treatment guidelines (1997, 2007, 2020) including as the principal author for the 2007 American Thoracic Society and Infectious Diseases Society of America Guidelines for the Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases. I am author or co-author on approximately 250 peer reviewed publications mostly pertaining to NTM disease including original research manuscripts, book chapters, reviews, editorials and electronic publications.


Baylor College of Medicine, Houston, TX
University of California, Santa Cruz, Santa Cruz, CA
Baylor College of Medicine, Houston, TX
Oregon Health & Sciences University, Portoland, OR
Baylor College of Medicine, Houston, TX
Oregon Health & Sciences University, Portland, OR

Awards & Recognition

2002-2019: W.A. and E.B. Moncrief Distinguished Professorship in Comprehensive Heart and Lung Research
2012: Murray Kornfeld Memorial Founders Lecture and Award, American College of Chest Physicians
2010-Present: Royal Society of Medicine, Overseas Fellow

Board Certification

1980: Internal Medicine
1986: Pulmonary Medicine

Professional Memberships

Fellow American College of Physicians
Fellow American College of Chest Physicians
Overseas Fellow, Royal Society of Medicine
American Thoracic Society


Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 Sep 14

Griffith DE, Flume PA, Thomson R, Mange K, Yuen DW, Morimoto K, Ruoss SJ, Codecasa LR, Yim Jae-Joon, Marras TK, van Ingen J, Wallace RJ, Brown Elliott BA, Coulter C, Winthrop KL.A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Subjects with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium Complex (MAC) That Are Refractory to Treatment (submitted)

104. Charles L. Daley, Jonathan M. Iaccarino, Christoph Lange, Emmanuelle Cambau, Richard J. Wallace Jr, Claire Andrejak, Erik C. Böttger, Jan Brozek, David E. Griffith, Lorenzo Guglielmetti, Gwen A. Huitt, Shandra L. Knight, Philip Leitman, Theodore K. Marras, Kenneth N. Olivier, Miguel Santin, Jason E. Stout, Enrico Tortoli, Jakko van Ingen, Dirk Wagner, Kevin L. Winthrop. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (In press, Clinical Infect Dis) 

Winthrop KL, Flume PA, Thomson R, Mange K, Yuen DW, Morimoto K, Ruoss SJ, Codecasa LR, Yim Jae-Joon, Marras TK, van Ingen J, Wallace RJ, Brown Elliott BA, Coulter C, Griffith DE. Safety and Tolerability of Amikacin Liposome Inhalation Suspension in Treatment-Refractory Mycobacterium avium complex Lung Disease: A 12-Month Open-Label Extension Study (submitted)

55. Griffith DE, Aksamit T, Brown-Elliott B, Catanzaro, Daley C, A Gordin F, Holland S, Horsburgh, Huitt G, Iademarco M, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Jr. An Official ATS/IDSA Statement: Diagnosis, Treatment and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007; 175: 367-416.

Teaching & Professional Positions

Professor of Medicine, University of TX Health Science Center, Tyler, TX
Professor of Medicine, National Jewish Health

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.

Ask a Question through Patient Portal

Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account

Contact Information

  • Office: 877.225.5654



  • National Jewish Health Main Campus
    1400 Jackson St.
    Denver, CO 80206

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes.

Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey.


Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.